HomeBUSINESS
BUSINESS

JCR’s Sakigake-Designated Hunter Syndrome Treatment Enters Japan PIII Study
(Aug.10.2018)

JCR Pharmaceuticals said on August 9 that it has commenced a PIII clinical study of its investigational Hunter syndrome therapeutic enzyme JR-141 in Japan ...
(LOG IN FOR FULL STORY)